Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.

Torres D, Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, Wang C, Langstraat CL, Cliby WA.

Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31420-3. doi: 10.1016/j.ygyno.2018.11.019. [Epub ahead of print]

PMID:
30503050
2.

Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.

Wagner BE, Langstraat CL, McGree ME, Weaver AL, Sarangi S, Mokri B, Dowdy SC, Cliby WA, Kumar A, Bakkum-Gamez JN.

Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31422-7. doi: 10.1016/j.ygyno.2018.11.021. [Epub ahead of print]

PMID:
30471900
3.

Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.

Zhang Q, Wang C, Cliby WA.

Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31415-X. doi: 10.1016/j.ygyno.2018.11.014. [Epub ahead of print]

PMID:
30448260
4.

Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies.

Tortorella L, Casarin J, Mara KC, Weaver AL, Multinu F, Glaser GE, Cliby WA, Scambia G, Mariani A, Kumar A.

Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31350-7. doi: 10.1016/j.ygyno.2018.10.036. [Epub ahead of print]

PMID:
30414740
5.

Quality indicators in gynecologic oncology.

Dowdy SC, Cliby WA, Famuyide AO.

Gynecol Oncol. 2018 Nov;151(2):366-373. doi: 10.1016/j.ygyno.2018.09.002. Epub 2018 Sep 13. Review. No abstract available.

PMID:
30220409
6.

Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.

Schlappe BA, Weaver AL, Ducie JA, Eriksson AGZ, Dowdy SC, Cliby WA, Glaser GE, Soslow RA, Alektiar KM, Makker V, Abu-Rustum NR, Mariani A, Leitao MM Jr.

Gynecol Oncol. 2018 Nov;151(2):235-242. doi: 10.1016/j.ygyno.2018.08.022. Epub 2018 Aug 31.

PMID:
30177461
7.

Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs.

Kumar A, Wallace SA, Cliby WA, Glaser GE, Mariani A, Leitao MM, Frumovitz M, Langstraat CL.

J Minim Invasive Gynecol. 2018 Aug 20. pii: S1553-4650(18)30406-0. doi: 10.1016/j.jmig.2018.08.006. [Epub ahead of print]

PMID:
30138740
8.

LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer.

Zhang Q, Hou X, Evans BJ, VanBlaricom JL, Weroha SJ, Cliby WA.

Cancers (Basel). 2018 Aug 7;10(8). pii: E260. doi: 10.3390/cancers10080260.

9.

Opportunistic salpingectomy to decrease the mortality from ovarian cancer: Can we expand the pool of eligible patients?

Bakkum-Gamez JN, Cliby WA.

Surgery. 2018 Nov;164(5):935-936. doi: 10.1016/j.surg.2018.05.004. Epub 2018 Jun 24. No abstract available.

PMID:
29945782
10.

Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.

Torres D, Wang C, Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, Konecny GE, Goode EL, Cliby WA.

Gynecol Oncol. 2018 Aug;150(2):227-232. doi: 10.1016/j.ygyno.2018.06.002. Epub 2018 Jun 18.

11.

Evidence-Based Screening Recommendations for Occult Cancers in the Setting of Newly Diagnosed Extramammary Paget Disease.

Schmitt AR, Long BJ, Weaver AL, McGree ME, Bakkum-Gamez JN, Brewer JD, Cliby WA.

Mayo Clin Proc. 2018 Jul;93(7):877-883. doi: 10.1016/j.mayocp.2018.02.024. Epub 2018 May 24.

PMID:
29804724
12.

Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy.

Wallace SK, Halverson JW, Jankowski CJ, DeJong SR, Weaver AL, Weinhold MR, Borah BJ, Moriarty JP, Cliby WA, Kor DJ, Higgins AA, Otto HA, Dowdy SC, Bakkum-Gamez JN.

Obstet Gynecol. 2018 May;131(5):891-898. doi: 10.1097/AOG.0000000000002463.

PMID:
29630007
13.

Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.

Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, Mariani A, Podratz KC.

Gynecol Oncol. 2018 May;149(2):291-296. doi: 10.1016/j.ygyno.2018.02.022. Epub 2018 Mar 14.

PMID:
29550183
14.

Adoption of Minimally Invasive Surgery and Decrease in Surgical Morbidity for Endometrial Cancer Treatment in the United States.

Casarin J, Multinu F, Ubl DS, Dowdy SC, Cliby WA, Glaser GE, Butler KA, Ghezzi F, Habermann EB, Mariani A.

Obstet Gynecol. 2018 Feb;131(2):304-311. doi: 10.1097/AOG.0000000000002428.

PMID:
29324598
15.

Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR.

Gill SE, Zhang Q, Keeney GL, Cliby WA, Weroha SJ.

Oncotarget. 2017 Jul 27;8(49):85214-85223. doi: 10.18632/oncotarget.19620. eCollection 2017 Oct 17.

16.

Need of informatics in designing interoperable clinical registries.

Rastegar-Mojarad M, Sohn S, Wang L, Shen F, Bleeker TC, Cliby WA, Liu H.

Int J Med Inform. 2017 Dec;108:78-84. doi: 10.1016/j.ijmedinf.2017.10.004. Epub 2017 Oct 10.

17.

Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.

Mert I, Kumar A, Sheedy SP, Weaver AL, McGree ME, Kim B, Cliby WA.

Gynecol Oncol. 2018 Jan;148(1):68-73. doi: 10.1016/j.ygyno.2017.10.024. Epub 2017 Nov 10.

PMID:
29129390
18.

Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease.

Ducie JA, Eriksson AGZ, Ali N, McGree ME, Weaver AL, Bogani G, Cliby WA, Dowdy SC, Bakkum-Gamez JN, Soslow RA, Keeney GL, Abu-Rustum NR, Mariani A, Leitao MM Jr.

Gynecol Oncol. 2017 Dec;147(3):541-548. doi: 10.1016/j.ygyno.2017.09.030. Epub 2017 Sep 29.

PMID:
28965698
19.

Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.

Torres D, Kumar A, Wallace SK, Bakkum-Gamez JN, Konecny GE, Weaver AL, McGree ME, Goode EL, Cliby WA, Wang C.

Gynecol Oncol. 2017 Dec;147(3):503-508. doi: 10.1016/j.ygyno.2017.09.021. Epub 2017 Sep 28.

20.

Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses.

Kumar A, Hurtt CC, Cliby WA, Martin JR, Weaver AL, McGree ME, Langstraat CL, Bakkum-Gamez JN.

Gynecol Oncol. 2017 Dec;147(3):514-520. doi: 10.1016/j.ygyno.2017.09.020. Epub 2017 Sep 22.

PMID:
28947173
21.

A matter of margins: Surgical and pathologic risk factors for recurrence in extramammary Paget's disease.

Long B, Schmitt AR, Weaver AL, McGree M, Bakkum-Gamez JN, Brewer J, Cliby WA.

Gynecol Oncol. 2017 Nov;147(2):358-363. doi: 10.1016/j.ygyno.2017.09.008. Epub 2017 Sep 19.

PMID:
28935274
22.

Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.

Kumar A, Langstraat CL, DeJong SR, McGree ME, Bakkum-Gamez JN, Weaver AL, LeBrasseur NK, Cliby WA.

Gynecol Oncol. 2017 Oct;147(1):104-109. doi: 10.1016/j.ygyno.2017.07.126. Epub 2017 Jul 19.

PMID:
28734497
23.

Clinical Utility of Preoperative Computed Tomography in Patients With Endometrial Cancer.

Bogani G, Gostout BS, Dowdy SC, Multinu F, Casarin J, Cliby WA, Frigerio L, Kim B, Weaver AL, Glaser GE, Mariani A.

Int J Gynecol Cancer. 2017 Oct;27(8):1685-1693. doi: 10.1097/IGC.0000000000001076.

PMID:
28704325
24.

Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer.

Kumar A, Torres ML, Cliby WA, Kalli KR, Bogani G, Aletti G, Nitschmann CC, Multinu F, Weaver AL, Block MS, Mariani A.

Anticancer Res. 2017 Jul;37(7):3673-3677.

PMID:
28668859
25.

Vaginal vs. robotic hysterectomy for patients with endometrial cancer: A comparison of outcomes and cost of care.

Nitschmann CC, Multinu F, Bakkum-Gamez JN, Langstraat CL, Occhino JA, Weaver AL, Cliby WA, Mariani A, Dowdy SC.

Gynecol Oncol. 2017 Jun;145(3):555-561. doi: 10.1016/j.ygyno.2017.03.002. Epub 2017 Apr 6.

PMID:
28392125
26.

Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study.

Leiserowitz GS, Lin JF, Tergas AI, Cliby WA, Bristow RE.

Int J Gynecol Cancer. 2017 May;27(4):675-683. doi: 10.1097/IGC.0000000000000967.

27.

Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.

Wang C, Armasu SM, Kalli KR, Maurer MJ, Heinzen EP, Keeney GL, Cliby WA, Oberg AL, Kaufmann SH, Goode EL.

Clin Cancer Res. 2017 Aug 1;23(15):4077-4085. doi: 10.1158/1078-0432.CCR-17-0246. Epub 2017 Mar 9.

28.

A prospective algorithm to reduce anastomotic leaks after rectosigmoid resection for gynecologic malignancies.

Kalogera E, Nitschmann CC, Dowdy SC, Cliby WA, Langstraat CL.

Gynecol Oncol. 2017 Feb;144(2):343-347. doi: 10.1016/j.ygyno.2016.11.032. Epub 2016 Dec 2.

PMID:
27919575
29.

Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.

Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.

Gynecol Oncol. 2017 Feb;144(2):266-273. doi: 10.1016/j.ygyno.2016.11.021. Epub 2016 Dec 1.

PMID:
27916269
30.

Abdominal Incision Injection of Liposomal Bupivacaine and Opioid Use After Laparotomy for Gynecologic Malignancies.

Kalogera E, Bakkum-Gamez JN, Weaver AL, Moriarty JP, Borah BJ, Langstraat CL, Jankowski CJ, Lovely JK, Cliby WA, Dowdy SC.

Obstet Gynecol. 2016 Nov;128(5):1009-1017.

PMID:
27741199
31.

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI.

Gynecol Oncol. 2016 Oct;143(1):3-15. doi: 10.1016/j.ygyno.2016.05.022. Epub 2016 Aug 8.

32.

In Reply.

Trabuco EC, Moorman PG, Cliby WA.

Obstet Gynecol. 2016 Sep;128(3):655-6. doi: 10.1097/AOG.0000000000001607. No abstract available.

PMID:
27548538
33.

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI.

J Clin Oncol. 2016 Oct 1;34(28):3460-73. doi: 10.1200/JCO.2016.68.6907. Epub 2016 Aug 8.

34.

Outcomes and Postoperative Complications After Hysterectomies Performed for Benign Compared With Malignant Indications.

Wallace SK, Fazzari MJ, Chen H, Cliby WA, Chalas E.

Obstet Gynecol. 2016 Sep;128(3):467-75. doi: 10.1097/AOG.0000000000001591.

PMID:
27500339
35.

Time for centralizing patients with ovarian cancer: what are we waiting for?

Aletti GD, Cliby WA.

Gynecol Oncol. 2016 Aug;142(2):209-10. doi: 10.1016/j.ygyno.2016.07.004. No abstract available.

PMID:
27452302
36.

Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.

Kumar A, Moynagh MR, Multinu F, Cliby WA, McGree ME, Weaver AL, Young PM, Bakkum-Gamez JN, Langstraat CL, Dowdy SC, Jatoi A, Mariani A.

Gynecol Oncol. 2016 Aug;142(2):311-6. doi: 10.1016/j.ygyno.2016.05.027. Epub 2016 Jun 2.

PMID:
27235857
37.

Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study.

Wallace SK, Lin JF, Cliby WA, Leiserowitz GS, Tergas AI, Bristow RE.

J Natl Compr Canc Netw. 2016 May;14(5):539-50.

PMID:
27160232
38.

Primary brain metastases of endometrial cancer: A report of 18 cases and review of the literature.

Uccella S, Morris JM, Multinu F, Cliby WA, Podratz KC, Gostout BS, Dowdy SC, Ghezzi F, Makdisi PB, Keeney GL, Link MJ, Mariani A.

Gynecol Oncol. 2016 Jul;142(1):70-75. doi: 10.1016/j.ygyno.2016.04.013. Epub 2016 Apr 26. Review.

PMID:
27095189
39.

Association of Ovary-Sparing Hysterectomy With Ovarian Reserve.

Trabuco EC, Moorman PG, Algeciras-Schimnich A, Weaver AL, Cliby WA.

Obstet Gynecol. 2016 May;127(5):819-27. doi: 10.1097/AOG.0000000000001398.

40.

Management of endometrial cancer: issues and controversies.

Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Frigerio L, Mariani A.

Eur J Gynaecol Oncol. 2016;37(1):6-12. Review.

PMID:
27048101
41.

Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.

Winterhoff B, Hamidi H, Wang C, Kalli KR, Fridley BL, Dering J, Chen HW, Cliby WA, Wang HJ, Dowdy S, Gostout BS, Keeney GL, Goode EL, Konecny GE.

Gynecol Oncol. 2016 Apr;141(1):95-100. doi: 10.1016/j.ygyno.2016.02.023.

42.

Incorporating robotic-assisted surgery for endometrial cancer staging: Analysis of morbidity and costs.

Bogani G, Multinu F, Dowdy SC, Cliby WA, Wilson TO, Gostout BS, Weaver AL, Borah BJ, Killian JM, Bijlani A, Angioni S, Mariani A.

Gynecol Oncol. 2016 May;141(2):218-224. doi: 10.1016/j.ygyno.2016.02.016. Epub 2016 Feb 16.

PMID:
26896826
43.

Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.

Janco JM, Kumar A, Weaver AL, McGree ME, Cliby WA.

Gynecol Oncol. 2016 Apr;141(1):140-7. doi: 10.1016/j.ygyno.2016.01.027. Epub 2016 Feb 2.

PMID:
26836496
44.

Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion.

Zahl Eriksson AG, Ducie J, Ali N, McGree ME, Weaver AL, Bogani G, Cliby WA, Dowdy SC, Bakkum-Gamez JN, Abu-Rustum NR, Mariani A, Leitao MM Jr.

Gynecol Oncol. 2016 Mar;140(3):394-9. doi: 10.1016/j.ygyno.2015.12.028. Epub 2015 Dec 31.

45.

The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts.

Al Hilli MM, Bakkum-Gamez JN, Mariani A, Cliby WA, Mc Gree ME, Weaver AL, Dowdy SC, Podratz KC.

Gynecol Oncol. 2016 Feb;140(2):270-6. doi: 10.1016/j.ygyno.2015.11.019. Epub 2015 Dec 1.

PMID:
26607780
46.

Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.

Kumar A, Janco JM, Mariani A, Bakkum-Gamez JN, Langstraat CL, Weaver AL, McGree ME, Cliby WA.

Gynecol Oncol. 2016 Jan;140(1):15-21. doi: 10.1016/j.ygyno.2015.10.025. Epub 2015 Nov 2.

PMID:
26541980
47.

Incisional Recurrences After Endometrial Cancer Surgery.

Bogani G, Dowdy SC, Cliby WA, Gostout BS, Kumar S, Ghezzi F, Multinu F, Mariani A.

Anticancer Res. 2015 Nov;35(11):6097-104.

PMID:
26504035
48.

Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples.

Hecht ES, Scholl EH, Walker SH, Taylor AD, Cliby WA, Motsinger-Reif AA, Muddiman DC.

J Proteome Res. 2015 Oct 2;14(10):4394-401. doi: 10.1021/acs.jproteome.5b00703. Epub 2015 Sep 14.

49.

There Is Nothing New Under the Sun.

Aletti GD, Bristow RE, Chi D, Cliby WA.

J Clin Oncol. 2015 Oct 20;33(30):3520. doi: 10.1200/JCO.2015.61.9536. Epub 2015 Aug 24. No abstract available.

PMID:
26304883
50.

Role of aggressive surgical cytoreduction in advanced ovarian cancer.

Chang SJ, Bristow RE, Chi DS, Cliby WA.

J Gynecol Oncol. 2015 Oct;26(4):336-42. doi: 10.3802/jgo.2015.26.4.336. Epub 2015 Jul 17. Review.

Supplemental Content

Loading ...
Support Center